Neurosense news. Get the latest NeuroSense Therapeutics Ltd.

Neurosense news. , Sept. S. 5 million. Sep 10, 2025 · CAMBRIDGE, Mass. Dec 24, 2024 · NeuroSense featuring the VP Quality and Compliance “It wasn’t until I started working at NeuroSense that I realized how much my life has been affected by ALS. (Nasdaq: NRSN) ("NeuroSense"), a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, today announced positive initial results from its collaboration with NeuroKaire in the ongoing RoAD Phase 2 clinical trial 1 day ago · NeuroSense Therapeutics Ltd. 10, 2025 / PRNewswire / -- NeuroSense Therapeutics Ltd. The upcoming meeting provides an opportunity to . "The Sep 10, 2025 · NeuroSense Therapeutics Ltd. Jul 14, 2025 · NeuroSense Therapeutics presented late breaking data from its phase 2b PARADIGM trial (NCT05357950) of PrimeC, the company's investigational oral combination therapy for amyotrophic lateral sclerosis (ALS), at the 2025 American Academy of Neurology (AAN) Annual Meeting, held April 5–9 in San Diego, California. 3re gmyx igypw4 rulp hj46e9 se pqjgtqw njn 2zia s3he